[HTML][HTML] Emerging biological treatments for uterine cervical carcinoma
P Vici, L Mariani, L Pizzuti, D Sergi, L Di Lauro… - Journal of …, 2014 - ncbi.nlm.nih.gov
Cervical cancer is the third most common cancer worldwide, and the development of new
diagnosis, prognostic, and treatment strategies is a major interest for public health. Cisplatin …
diagnosis, prognostic, and treatment strategies is a major interest for public health. Cisplatin …
Update on novel therapeutic agents for cervical cancer
JM del Campo, A Prat, A Gil-Moreno, J Pérez… - Gynecologic …, 2008 - Elsevier
Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited.
Cisplatin-based combination chemotherapy, the most commonly used cytotoxic therapy, has …
Cisplatin-based combination chemotherapy, the most commonly used cytotoxic therapy, has …
Targeted agents in cervical cancer: beyond bevacizumab
G Marquina, A Manzano, A Casado - Current oncology reports, 2018 - Springer
Cervical cancer constitutes a leading cause of morbidity and cancer deaths in women
throughout the world. Approximately two thirds of the patients are diagnosed with locally …
throughout the world. Approximately two thirds of the patients are diagnosed with locally …
New molecular targets against cervical cancer
A Duenas-Gonzalez, A Serrano-Olvera… - … journal of women's …, 2014 - Taylor & Francis
Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth
leading cause of cancer death in women. Major advances but still insufficient achievements …
leading cause of cancer death in women. Major advances but still insufficient achievements …
Investigational drugs for the treatment of cervical cancer
F Barra, D Lorusso… - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: Cervical cancer (CC) is currently the fourth most common malignant disease of
women worldwide. Although the incidence and the mortality rates have been decreasing …
women worldwide. Although the incidence and the mortality rates have been decreasing …
Emerging drugs for the treatment of cervical cancer
A Serrano-Olvera, L Cetina, J Coronel… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: Worldwide, most cervical cancer (CC) patients require the use of drug therapy
either adjuvant, concurrent with radiation or palliative. Areas covered: This review briefly …
either adjuvant, concurrent with radiation or palliative. Areas covered: This review briefly …
Molecularly targeted therapies in cervical cancer. A systematic review
Cervical cancer represents the third most common cause of female cancer mortality. Even
with the best currently available treatment, a significant proportion of patients will experience …
with the best currently available treatment, a significant proportion of patients will experience …
Advances in cervical cancer pharmacotherapies
M Markman - Expert Review of Clinical Pharmacology, 2014 - Taylor & Francis
While widely employed in the management of cervical cancer, the overall utility of systemic
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …
anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most …
Emerging drugs for cervical cancer
A Duenas-Gonzalez, L Cetina, J Coronel… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: There is a shortage of therapeutical agents for invasive cervical cancer in late
stages of development; however, a number of promising molecules are currently in early …
stages of development; however, a number of promising molecules are currently in early …
[HTML][HTML] Updates on systemic therapy for cervical cancer
P Gopu, F Antony, S Cyriac, K Karakasis… - Indian Journal of …, 2021 - journals.lww.com
Cervical cancer is one of the most common cancers in the world both in terms of incidence
and mortality, more so important in low-and middle-income countries. Surgery and …
and mortality, more so important in low-and middle-income countries. Surgery and …